Development of a Diagnostic Genetic Test for Simplex and Autosomal Recessive Retinitis Pigmentosa

详细信息    查看全文

• 作者：Graeme Richard Clark ; Paul Crowe ; Dorota Muszynska ; Dominic O'Prey ; Justin O'Neill ; Sharon Alex ; er ; Colin Eric Willoughby ; Gareth John McKay ; Giuliana Silvestri ; David Arthur Simpson
• 刊名：Ophthalmology
• 出版年：2010
• 出版时间：November 2010
• 年：2010
• 卷：117
• 期：11
• 页码：2169-2177.e3
• 全文大小：1325 K

文摘

Purpose

Retinitis pigmentosa (RP) causes hereditary blindness in adults (prevalence, approximately 1 in 4000). Each of the more than 30 causative genes identified to date are responsible for only a small percentage of cases. Genetic diagnosis via traditional methods is problematic, and a single test with a higher probability of detecting the causative mutation would be very beneficial for the clinician. The goal of this study therefore was to develop a high-throughput screen capable of detecting both known mutations and novel mutations within all genes implicated in autosomal recessive or simplex RP.

Design

Evaluation of diagnostic technology.

Participants and Controls

Participants were 56 simplex and autosomal recessive RP patients, with 360 population controls unscreened for ophthalmic disease.

Methods

A custom genechip capable of resequencing all exons containing known mutations in 19 disease-associated genes was developed (RP genechip). A second, commercially available arrayed primer extension (APEX) system was used to screen 501 individual previously reported variants. The ability of these high-throughput approaches to identify pathogenic variants was assessed in a cohort of simplex and autosomal recessive RP patients.

Main Outcome Measures

Number of mutations and potentially pathogenic variants identified.

Results

The RP genechip identified 44 sequence variants: 5 previously reported mutations; 22 known single nucleotide polymorphisms (SNPs); 11 novel, potentially pathogenic variants; and 6 novel SNPs. There was strong concordance with the APEX array, but only the RP genechip detected novel variants. For example, identification of a novel mutation in CRB1 revealed a patient, who also had a single previously known CRB1 mutation, to be a compound heterozygote. In some individuals, potentially pathogenic variants were discovered in more than one gene, consistent with the existence of disease modifier effects resulting from mutations at a second locus.

Conclusions

The RP genechip provides the significant advantage of detecting novel variants and could be expected to detect at least one pathogenic variant in more than 50 % of patients. The APEX array provides a reliable method to detect known pathogenic variants in autosomal recessive RP and simplex RP patients and is commercially available. High-throughput genotyping for RP is evolving into a clinically useful genetic diagnostic tool.

Financial Disclosure(s)

The author(s) have no proprietary or commercial interest in any materials discussed in this article.